UY37808A - Nuevos compuestos que inhiben la actividad quinasa de la lrrk2 - Google Patents

Nuevos compuestos que inhiben la actividad quinasa de la lrrk2

Info

Publication number
UY37808A
UY37808A UY0001037808A UY37808A UY37808A UY 37808 A UY37808 A UY 37808A UY 0001037808 A UY0001037808 A UY 0001037808A UY 37808 A UY37808 A UY 37808A UY 37808 A UY37808 A UY 37808A
Authority
UY
Uruguay
Prior art keywords
lrrk2
inhibit
new compounds
kinase activity
disease
Prior art date
Application number
UY0001037808A
Other languages
English (en)
Inventor
Feng Ren
Xiao Ding
Ming-Hsun Ho
Haihua Yu
Yang Zhan
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY37808A publication Critical patent/UY37808A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención se refiere a nuevos compuestos que inhiben la actividad quinasa de la LRRK2, a procesos para su preparación, a composiciones que los contienen y a su uso en el tratamiento de, o prevención de, enfermedades asociadas con, o caracterizadas por, la actividad quinasa de la LRRK2, por ejemplo la enfermedad de Parkinson, enfermedad de Alzheimer y esclerosis lateral amiotrófica (ELA).
UY0001037808A 2017-07-14 2018-07-12 Nuevos compuestos que inhiben la actividad quinasa de la lrrk2 UY37808A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2017093024 2017-07-14

Publications (1)

Publication Number Publication Date
UY37808A true UY37808A (es) 2019-02-28

Family

ID=62916682

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037808A UY37808A (es) 2017-07-14 2018-07-12 Nuevos compuestos que inhiben la actividad quinasa de la lrrk2

Country Status (10)

Country Link
US (1) US20200392158A1 (es)
EP (1) EP3652179A1 (es)
JP (1) JP2020526543A (es)
CN (1) CN110891954A (es)
AR (1) AR112392A1 (es)
BR (1) BR112020000772A2 (es)
CA (1) CA3069554A1 (es)
TW (1) TW201920197A (es)
UY (1) UY37808A (es)
WO (1) WO2019012093A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020257165A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
JP2022537385A (ja) * 2019-06-19 2022-08-25 ターニング・ポイント・セラピューティクス・インコーポレイテッド 大環状キナーゼ阻害剤の多形
WO2020257189A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for treating disease
EP3769768A1 (en) 2019-07-23 2021-01-27 Consejo Superior de Investigaciones Cientificas (CSIC) Compounds useful for the treatment of parkinson s disease
TW202208379A (zh) 2020-05-06 2022-03-01 法商施維雅藥廠 新穎的巨環lrrk2激酶抑制劑
BR112023017834A2 (pt) 2021-03-18 2023-10-03 Servier Lab Inibidores de lrrk2 cinase macrocíclicos
AR127470A1 (es) 2021-10-27 2024-01-31 H Lundbeck As Inhibidores de lrrk2
WO2023220247A1 (en) * 2022-05-12 2023-11-16 Interline Therapeutics, Inc. Lrrk2 inhibitors
CN117425660A (zh) * 2022-05-18 2024-01-19 上海翊石医药科技有限公司 一种芳杂环类化合物及其中间体、药物组合物和用途
WO2023224894A1 (en) * 2022-05-20 2023-11-23 Merck Sharp & Dohme Llc Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
US11958865B1 (en) 2022-09-15 2024-04-16 H. Lundbeck A/S Leucine-rich repeat kinase 2 (LRRK2) inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DK1802749T3 (da) 2004-10-21 2012-11-26 Mayo Foundation KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
CN101473044A (zh) 2006-06-20 2009-07-01 诺瓦提斯公司 阿尔茨海默病进展的生物标记
HUE037844T2 (hu) * 2010-11-10 2018-09-28 Genentech Inc Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
PT2760453T (pt) * 2011-09-30 2016-08-02 Ipsen Pharma Sas Inibidores macrocíclicos da cinase lrrk2
AR101265A1 (es) 2014-07-22 2016-12-07 Boehringer Ingelheim Int Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble

Also Published As

Publication number Publication date
AR112392A1 (es) 2019-10-23
WO2019012093A1 (en) 2019-01-17
EP3652179A1 (en) 2020-05-20
CN110891954A (zh) 2020-03-17
BR112020000772A2 (pt) 2020-07-21
JP2020526543A (ja) 2020-08-31
TW201920197A (zh) 2019-06-01
US20200392158A1 (en) 2020-12-17
CA3069554A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
UY37808A (es) Nuevos compuestos que inhiben la actividad quinasa de la lrrk2
DOP2016000195A (es) Compuestos
BR112018001303A2 (pt) ?compostos?
UY37580A (es) Compuestos novedosos que inhiben la actividad de cinasa lrrk2
CO2017011851A2 (es) Compuestos novedosos
CL2018002703A1 (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291)
BR112018074185A2 (pt) 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas
SV2018005771A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
MX2020013853A (es) Compuestos innovadores.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
UY37606A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
BR112016005881A2 (pt) composto, composição farmacêutica e uso do composto
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UY35628A (es) ?compuestos heteroaromáticos y su uso como ligandos d1 de dopamina?.
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112018010564A2 (pt) composições farmacêuticas compreendendo levodopa amida e usos das mesmas
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
MX2021003905A (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.
BR112017008045A2 (pt) compostos como inibidores de nik
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
CL2020000070A1 (es) Agentes, usos y métodos para el tratamiento.